Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/31/2025

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Diagnosis and Management

Clinical Presentation and Diagnosis

  • The American Society of Clinical Oncology recommends that CIPN symptoms typically emerge within the first 2 months of treatment with neurotoxic chemotherapy, exactly when this patient's symptoms began 1, 2
  • Numbness and tingling are the earliest and most prominent symptoms of CIPN, appearing before pain develops 1
  • CIPN follows a "stocking-glove" pattern, starting distally in fingers and toes and progressing proximally if worsening 1, 2
  • Symptoms should be bilateral and symmetrical 2
  • Primarily numbness and tingling, with motor symptoms (weakness, tremor) appearing much less commonly 1, 2

Management and Treatment

  • The American Society of Clinical Oncology recommends assessing severity and impact on quality of life using a simple pain scale at every encounter 1, 3, 4, 5
  • Duloxetine 30 mg daily for 1 week, then increase to 60 mg daily, is the ONLY medication with Level 1 evidence showing 30-50% relative risk reduction in neuropathic pain, numbness, and tingling 3, 4
  • Physical activity has been shown to improve neuropathy symptoms in multiple RCTs 3, 4, 5
  • Acupuncture has Level IB evidence for neuropathic pain in cancer survivors, though specific evidence for CIPN is limited 3, 4, 6

Prognosis and Follow-Up

  • If receiving paclitaxel, symptoms typically improve over several months after chemotherapy completion 1
  • If receiving oxaliplatin, expect "coasting phenomenon": symptoms worsen for 2-3 months AFTER stopping chemotherapy 1
  • A subset of patients experience persistent, debilitating neuropathy for years despite treatment cessation 1
  • At every clinical encounter, assess neuropathy symptoms using standardized questions about numbness, tingling, and pain characteristics 3, 4, 5, 6

Evidence‑Based Management of Chemotherapy‑Induced Peripheral Neuropathy

Clinical Presentation

  • CIPN manifests predominantly with sensory deficits—including numbness, tingling, burning pain, and reduced perception of light touch, vibration, and proprioception—in patients receiving neurotoxic chemotherapy agents such as taxanes and platinum compounds. Level of evidence: observational cohort data. 7

Pathophysiology

  • The neuropathy arises from damage to peripheral sensory axons caused by exposure to taxane agents (e.g., paclitaxel) and platinum agents (e.g., cisplatin, oxaliplatin). Level of evidence: mechanistic studies and clinical correlation. 7

Pharmacologic Intervention

  • A duloxetine regimen starting at 30 mg daily for one week and titrating to 60 mg daily provides a Level 1 evidence‑based 30‑50 % relative risk reduction in neuropathic pain, numbness, and tingling for patients with CIPN. Strength of evidence: randomized, placebo‑controlled trial. [8][7]
  • Early initiation of duloxetine—without waiting for spontaneous improvement—offers the greatest chance for symptom control and preservation of quality of life. Strength of evidence: same high‑quality trial supporting the above dosing. [8][7]

Non‑pharmacologic Intervention

  • Structured physical activity programs have Level IA evidence for improving CIPN symptoms and should be offered promptly to affected patients. Strength of evidence: meta‑analysis of randomized trials. 7

Monitoring and Assessment

  • At every clinical encounter, severity should be assessed using a simple pain scale to determine impact on quality of life and functional status, guiding treatment adjustments. Level of evidence: expert consensus supported by trial data. [8][7]